Neorich Biopharma Tech Co., Limited

As of June 30, 2023, Neorich Biopharma Tech Co., Limited carries a market capitalization of 1.62B, placing it among publicly traded companies globally. Its enterprise value stands at 1.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2023, Neorich Biopharma Tech Co., Limited has 463.96M shares outstanding.

These figures are as of June 30, 2023. The price-to-sales ratio is 755,306.96, and the price-to-book ratio stands at -771.68.

These figures are as of June 30, 2023. The EV/Sales ratio of 1.04M reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.62B versus a market cap of 1.62B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2023, Neorich Biopharma Tech Co., Limited maintains a current ratio of 0.02, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -18.57, indicating conservative leverage, while an interest coverage ratio of -5.85 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2023. Return on assets (ROA) is negative at -302.07, reflecting losses generated across the asset base.

As of the close on September 8, 2026, Neorich Biopharma Tech Co., Limited's stock has declined approximately 77.50% over the past 52 weeks. The 50-day moving average sits at 113.60, while the 200-day moving average is 31.34.

Over the twelve months ended June 30, 2023, Neorich Biopharma Tech Co., Limited generated 1,560.00 in revenue and converted that into -500,657.00 in net income, yielding earnings per share of 0.00. EBITDA reached -558,590.00, while operating income came in at -558,590.00.

As of June 30, 2023, Neorich Biopharma Tech Co., Limited holds 5,315.00 in cash and equivalents against 399,474.00 in total debt, resulting in a net debt position of 394,159.00. Total book value stands at -2.10M, with working capital of -2.12M providing operational flexibility.

Neorich Biopharma Tech Co., Limited produced -138,511.00 in operating cash flow over the twelve months ended June 30, 2023.

These figures cover the twelve months ended June 30, 2023. The operating margin of -35,807.05 and net profit margin of -32,093.40 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2023. Free cash flow yield is negative at -0.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.01, meaning Neorich Biopharma Tech Co., Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Neorich Biopharma Tech Co., Limited's most recent stock split took place on August 14, 2026.

As of June 30, 2023, Neorich Biopharma Tech Co., Limited has an Altman Z-Score of 264.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.